Showing results (51-60 of 95) with videos related to
Sort By:
Pageof 10
Journal of Cancer Research and Clinical Oncology|October 12, 2012
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practiceDomenico Angelucci, Nicola Tinari, Antonino Grassadonia, et al.Oncotarget|March 20, 2016
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusGiuseppe Bronte, Tindara Franchina, Massimiliano Alù, et al.Oncology Letters|February 14, 2018
A multidisciplinary group for prostate cancer management: A single institution experienceAntonella Colasante, Antonietta Augurio, Raffaella Basilico, et al.Breast (Edinburgh, Scotland)|January 6, 2019
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patientsVincenzo Graziano, Antonino Grassadonia, Laura Iezzi, et al.Annals of Surgical Oncology|February 14, 2014
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancerAntonino Grassadonia, Marta Di Nicola, Simona Grossi, et al.Journal of Cancer|November 26, 2019
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future ScenariosLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.Cancer|May 4, 2018
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysisAntonios Valachis, Eleftherios P Mamounas, Elizabeth A Mittendorf, et al.BMC Cancer|February 8, 2017
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancerMaddalena Barba, Patrizia Vici, Laura Pizzuti, et al.Oncotarget|October 9, 2014
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapyPatrizia Vici, Marcella Mottolese, Laura Pizzuti, et al.Journal of Cancer Research and Clinical Oncology|April 23, 2013
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancerClara Natoli, Patrizia Vici, Isabella Sperduti, et al.Pageof 10